SCRIBE THERAPEUTICS INC. (SCTX) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $14.00K; Additional Paid in CapitalUSD $16.67M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-2.00K; Retained Earnings (Accumulated Deficit)USD $-181.53M.
- 2026-03-31: Common Stock, Value, IssuedUSD (m); Additional Paid in CapitalUSD (m); Accumulated Other Comprehensive Income (Loss), Net of TaxUSD (m); Retained Earnings (Accumulated Deficit)USD (m).
- 2025-12-31: Common Stock, Value, IssuedUSD $14.00K; Additional Paid in CapitalUSD $14.24M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $35.00K; Retained Earnings (Accumulated Deficit)USD $-157.71M.
- 2025-06-30: Common Stock, Value, IssuedUSD (m); Additional Paid in CapitalUSD (m); Accumulated Other Comprehensive Income (Loss), Net of TaxUSD (m); Retained Earnings (Accumulated Deficit)USD (m).
SCRIBE THERAPEUTICS INC. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD |
|---|---|---|---|---|---|---|
| 2026-06-30 | $14.00K | $16.67M | $-2.00K | $-181.53M | $-164.85M | 3 month · $227.00K |
| 2026-03-31 | (m) | (m) | (m) | (m) | $-158.74M | 3 month · $1.97M |
| 2025-12-31 | $14.00K | $14.24M | $35.00K | $-157.71M | $-143.42M | (m) |
| 2025-06-30 | (m) | (m) | (m) | (m) | $-137.88M | 3 month · $676.00K |
| 2025-03-31 | (m) | (m) | (m) | (m) | $-128.67M | 3 month · $671.00K |
| 2024-12-31 | (m) | (m) | (m) | (m) | $-125.86M | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |